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Abstract
Mesenchymal stem cells (MSCs) are a promising cell population for cell-based bone repair due to their proliferative
potential, ability to differentiate into bone-forming osteoblasts, and their secretion of potent trophic factors that stimulate
angiogenesis and neovascularization. To promote bone healing, autogenous or allogeneic MSCs are transplanted into bone
defects after differentiation to varying degrees down the osteogenic lineage. However, the contribution of the stage of
osteogenic differentiation upon angiogenic factor secretion is unclear. We hypothesized that the proangiogenic potential of
MSCs was dependent upon their stage of osteogenic differentiation. After 7 days of culture, we observed the greatest
osteogenic differentiation of MSCs when cells were cultured with dexamethasone (OM+). Conversely, VEGF protein
secretion and upregulation of angiogenic genes were greatest in MSCs cultured in growth media (GM). Using conditioned
media from MSCs in each culture condition, GM-conditioned media maximized proliferation and enhanced chemotactic
migration and tubule formation of endothelial colony forming cells (ECFCs). The addition of a neutralizing VEGF165/121
antibody to conditioned media attenuated ECFC proliferation and chemotactic migration. ECFCs seeded on microcarrier
beads and co-cultured with MSCs previously cultured in GM in a fibrin gel exhibited superior sprouting compared to MSCs
previously cultured in OM+. These results confirm that MSCs induced farther down the osteogenic lineage possess reduced
proangiogenic potential, thereby providing important findings for consideration when using MSCs for bone repair.
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Introduction
Cell survival requires appropriate access of nutrients and close
proximity to capillaries, and thus, limited vascularization at an
injury site remains a primary obstacle in tissue engineered
therapies [1]. Transport limitations of tissue engineered constructs
can be potentially resolved by establishing a new vasculature
within the new tissue, and current studies aim to promote
vascularization within growing tissues through vasculogenesis or
angiogenesis. For example, smooth muscle cells have been
transduced to overexpress vascular endothelial growth factor
(VEGF), a potent mitogen which stimulates angiogenesis through
proliferation and migration of endothelial cells [2].
Recent efforts have focused on coupling angiogenesis to bone
repair since natural development and formation of the skeleton
occurs in close proximity to vascular ingrowth [3–6]. Vasculature
provides growth factors, hormones, cytokines, and chemokines
required by the bone tissue, and vasculature disruption can lead to
skeletal pathologies such as osteonecrosis and osteomyelitis [7].
Indeed, Huang et al. demonstrated that combining angiogenic and
osteogenic factors exhibited increased bone formation in vivo
compared to either factor alone [5], demonstrating the crucial
interdependence of the two processes for bone repair.
Mesenchymal stem cells (MSCs) are an attractive cell source for
use in tissue engineering due to their proliferative potential,
multipotency, and immunomodulatory effects [8–10]. In addition
to other phenotypes, MSCs can be induced toward the osteoblastic
lineage when cultured in osteoinductive conditions [11] or placed
on osteoconductive materials [12]. Furthermore, MSCs secrete
multiple trophic factors that suppress the immune system [13],
inhibit apoptosis [14], stimulate mitosis [15] and differentiation
[8–10], and enhance angiogenesis [14,16]. The benefits of MSC
trophic factor secretion have been confirmed using co-cultures
with endothelial cell populations [3], as well as conditioned media
[4] from MSCs. When transplanted in vivo, MSCs enhance and
accelerate angiogenesis and stabilize new blood vessels [16].
The composition of cell culture media has a significant effect on
MSC cytokine expression [17,18]. Media supplemented with
cocktails of specific components at precise concentrations can
effectively drive MSCs toward distinct phenotypes such as bone,
cartilage, and fat [11]. To stimulate the production of inorganic
and organic components in bone, MSCs can be cultured in media
supplemented with combinations of ascorbic acid, b-glycerophos-
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phate, and dexamethasone. Specifically, ascorbic acid increases
synthesis of collagen and extracellular matrix and b-glycerophos-
phate provides phosphate ions to promote hydroxyapatite
formation [19]. Dexamethasone, a potent glucocorticoid, also
facilitates mineralization by increasing alkaline phosphatase
activity and cyclic adenosine monophosphate (cAMP) responses
to parathyroid hormone (PTH) and prostaglandin [20,21].
However, not all differentiation protocols include dexamethasone
in the osteoinductive cocktail [22,23], since glucocorticoids have
been shown to inhibit collagen type I and osteocalcin expression in
osteoblasts [24]. The inclusion of cocktail components directs
osteogenic differentiation of MSCs to varying degrees, but the
contribution of osteogenic differentiation on trophic factor
secretion is poorly understood [17].
We hypothesized the secretion of proangiogenic trophic factors
by MSCs was a function of the stage of differentiation down the
osteogenic lineage. To explore this hypothesis, we measured the
quantity and bioactivity of endogenous proangiogenic factors from
MSCs when osteogenically induced in different culture media.
Furthermore, we examined the capacity of osteogenically-induced
MSCs to contribute to capillary sprouting and stabilization when
co-cultured with endothelial cells in fibrin gels. The results of these
studies provide an improved understanding of the balance
between MSC differentiation and trophic factor secretion for use
as a cell-based therapy for bone regeneration and repair.
Results
Dexamethasone enhances osteogenic differentiation
MSCs were cultured for 7 days in growth media (GM),
osteogenic media (OM), or osteogenic media supplemented with
dexamethasone (OM+) (Table 1) and analyzed for alkaline
phosphatase (ALP) activity, an early marker of osteogenic
differentiation. The addition of dexamethasone to the culture
media increased intracellular ALP production. Compared to
MSCs in GM (Fig. 1A) or OM (Fig. 1B), staining intensity for
ALP in MSC was increased for cells in OM+ (Fig. 1C). MSCs
cultured in OM did not exhibit significant increases in ALP
activity after 7 days of culture. These qualitative observations were
corroborated by quantification of intracellular ALP activity
(Fig. 1D).
Proangiogenic potential of MSCs is impaired by
osteogenic differentiation
After 7 days, MSCs cultured in each media composition were
analyzed for expression of angiogenic (FGF2, PDGFB, TGFB1, and
VEGFA) and osteogenic markers (COL1A1, IBSP, and SP7). Cells
cultured in OM+ exhibited increased expression of osteogenic
genes (Fig. 2A–C) and conversely, decreased expression of
angiogenic genes (Fig. 2D–F). In all groups, expression of PDGFB
was not detected (data not shown).
The concentration of secreted VEGF was greatest for MSCs
cultured in GM. The addition of osteogenic supplements to the
culture media decreased VEGF secretion (Fig. 3). Cells cultured
in OM+ secreted VEGF quantities that were significantly less than
MSCs cultured in GM or OM. We quantified the production of
proangiogenic proteins in response to GM, OM, or OM+. Serum
alone did not exhibit detectably distinct levels of angiogenic
cytokines compared to conditioned media (Fig. 4A, B). A stacked
column chart of the predominant angiogenic cytokines (100–1000-
fold greatest) reveals MSCs conditioned in GM secreted the
highest concentrations of angiogenic cytokines, whereas MSCs
conditioned in OM secreted the lowest (Fig. 4C). Concentrations
of most angiogenic factors decreased as media included more
osteogenic supplements. In contrast, angiogenin and RANTES
(CCL5) concentration notably increased. VEGF concentration
determined through the angiogenic protein array decreased with
osteogenic media (Fig. 4D).
ECFC proliferation, migration, and tubule formation is
altered by MSC conditioned media
ECFCs exhibited the greatest proliferation when stimulated
with conditioned media from cells in GM, followed by OM and
OM+ (Fig. 5). The addition of a neutralizing VEGF165/121
antibody significantly attenuated proliferation in GM and OM,
whereas the effect was less pronounced for OM+. Conditioned
GM and OM induced significantly greater ECFC proliferation
than unconditioned GM and OM, respectively, indicating that
secretion of trophic factors from MSCs, and not media
composition alone, was responsible for the observed changes in
ECFC proliferation. No significant differences in proliferation
were observed among unconditioned medias.
ECFC migration toward conditioned GM through a transwell
insert increased 12-fold compared to no gradient (Fig. 6A, E), and
chemotaxis to GM was significantly greater than ECFC migration
toward conditioned OM (Fig. 6C) and OM+ (Fig. 6D). The
addition of a neutralizing VEGF165/121 antibody significant
reduced ECFC migration in response to conditioned GM
(Fig. 6B).
Using Matrigel as a basement membrane, we observed similar
branch point frequency in ECFC-derived tubules with conditioned
media from MSCs cultured in GM (Fig. 7A) or OM (Fig. 7C).
We quantified fewer branch points in ECFCs grown in media
from OM+-cultured MSCs (Fig. 7D). Quantification of branch
points as an indicator of sprouting revealed a significant reduction
for ECFCs cultured in OM+-conditioned media (Fig. 7E), and we
observed a similar trend when quantifying average tubule length
(Fig. 7F). The addition of neutralizing VEGF165/121 antibody did
not significantly alter any tubule parameters except the arbitrary
number of disrupted tubules, which is qualitatively illustrated in
the comparison between Fig. 7A and Fig. 7B.
Osteogenic differentiation reduces capillary sprouting
GFP-ECFCs seeded on microcarrier beads were co-cultured
with CellTrackerTM Orange-labeled MSCs, pre-conditioned in
each media for 7 days, and uniformly distributed throughout the
fibrin gel (Fig. 8A). Co-cultures with GM-conditioned MSCs
(Fig. 8B) exhibited visually improved sprouting compared to
MSCs cultured in OM (Fig. 8C) and OM+ (Fig. 8D).
Quantitative analysis revealed GM-conditioned MSCs increased
average sprout number per bead (Fig. 8E) and average sprout
length (Fig. 8F) compared to other cells. For all groups, sprouting
parameters increased until 2 days and plateaued by 3 days.
Discussion
Human MSCs were differentiated to varying degrees in
osteogenic media to test our hypothesis that the secretion of
proangiogenic factors by MSCs was a function of their stage of
osteogenic differentiation. When stimulating ECFCs to measure
proangiogenic potential, conditioned media from MSCs cultured
in growth media resulted in increased angiogenic stimulation
compared to MSCs in either osteogenic media. Moreover, MSCs
differentiated in dexamethasone-containing osteogenic media
(OM+) exhibited minimal angiogenic potential for all studies.
These findings indicate that osteogenically-differentiated MSCs
have a limited capacity to support angiogenesis, and thus, these
Proangiogenic Potential of MSCs
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data highlight the importance of considering modulations of MSC
trophic factor secretion due to culture conditions.
The addition of dexamethasone to osteogenic supplements
significantly increased differentiation of MSCs within 7 days
compared to growth media or osteogenic media without
dexamethasone. ALP activity, along with COL1A1, IBSP, and
SP7 gene expression, was greatest in cells maintained in OM+.
MSCs in osteogenic media lacking dexamethasone did not exhibit
significant increases in osteogenic markers after 7 days, suggesting
that longer periods of culture are required to effectively
differentiate MSCs without this corticosteroid. Dexamethasone
stimulates MSC differentiation into osteoblasts by increasing ALP
activity among other mechanisms [20,21]. However, not all
protocols utilize this molecule as an osteogenic supplement [22,23]
because it decreases MSC production cytokines such as leukemia
inhibitory factor (LIF), interleukin-6 (IL-6), and interleukin-11 (IL-
11), which decrease osteocalcin and may inhibit osteoblast
differentiation [17].
Angiogenesis, a crucial event in bone formation, involves
capillary-forming endothelial cells that are stimulated by proan-
giogenic factors [25]. MSCs secrete numerous trophic and
angiogenic factors such as VEGF, a potent soluble cue that
induces migration and proliferation of endothelial cells and
stimulates neovascularization [26]. In these studies, MSCs
cultured in GM secreted the highest concentrations of VEGF. In
contrast, MSCs cultured in osteogenic media downregulate gene
expression of the proangiogenic factors VEGFA, TGFB1, and FGF2
[27]. ECFCs exhibited the greatest mitogenic response when
stimulated with conditioned media of MSCs cultured in GM,
which was shown to contain the highest concentration of VEGF
and other proangiogenic cytokines. Interleukins 6 and 8 (IL-6 and
IL-8) are prominent angiogenic cytokines found in conditioned
growth media are generally secreted by leukocytes, macrophages,
and other cell types such as MSCs as part of the immune response
to regulate hematopoietic cell development and differentiation.
Both IL-6 and IL-8 concentrations decreased from GM to OM+,
which confirms evidence that dexamethasone decreases IL-6
production [17]. Interaction among these and other angiogenic
cytokines and the subsequent autocrine and paracrine effects
merits further exploration.
OM+-cultured MSCs were most differentiated toward osteo-
blasts and secreted minimal VEGF. VEGF-A is secreted in a
differentiation-dependent manner during osteogenesis and peaks
upon mineralization after osteogenic culture for 7 weeks [28] and
Figure 1. Cytochemical stains and biochemical quantification of ALP activity in MSCs after 7 days. MSCs cultured in (A) GM, (B) OM, and
(C) OM+. Scale bars represent 200 mm. (D) Quantification of intracellular ALP activity in MSCs as a function of media composition. Chart values
represent mean 6 SD for n = 4; {p,0.001 vs. GM and OM.
doi:10.1371/journal.pone.0035579.g001
Table 1. Cell culture media and composition.
Name Media Supplements
GM a-MEM, 10% FBS, 1% P/S -
OM a-MEM, 10% FBS, 1% P/S 10 mM bGP, 50 mg/mL A2P
OM+ a-MEM, 10% FBS, 1% P/S 10 mM bGP, 50 mg/mL A2P, 10 nM dexamethasone
EBM2 EBM2 -
GF-Def EGM2 EBM2, 10% FBS, 1% P/S Hydrocortisone, gentamycin-1000, EGF, heparin
EGM2 EBM2, 10% FBS, 1% P/S Hydrocortisone, gentamycin-1000, EGF, heparin, VEGF, FGF, IGF
doi:10.1371/journal.pone.0035579.t001
Proangiogenic Potential of MSCs
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18 days [29]; however, the effects of VEGF secretion in direct
application to endothelial cells have not been thoroughly
investigated. VEGF-A exists in 5 different isoforms. Whereas
VEGF165 is detected at all stages during early osteogenesis,
VEGF121 principally serves as the primary angiogenic factor in
early osteogenesis [30]. A polyclonal VEGF165/121 neutralizing
antibody was added to the proliferation, migration, and Matrigel
tubule formation assays. The antibody significantly inhibited
ECFC proliferation and migration in response to conditioned GM,
demonstrating that VEGF secreted by MSCs in conditioned
media is responsible for its subsequent angiogenic effects on
endothelial cells. While the antibody disrupted tubule formation, it
did not lead to a significant decrease in number of tubule branches
or length of tubules. Such data is in agreement with previous
reports in which the addition of VEGF neutralizing antibodies did
not affect average number of tubule branches [31]. The ability of
VEGF to promote vascularization has spawned therapies to
incorporate the protein either through entrapment in scaffolds
[32,33] or bolus injection [34]; however, both methods expose
severe limitations. The short half-life of VEGF leads to rapid
biodegradation and a bolus injection may cause hypertension [2].
Therefore, sustained, localized delivery of physiological concen-
trations of VEGF through MSC secretion offers a promising
alternative to stimulate angiogenesis.
Figure 2. qPCR expression of osteogenic and angiogenic marker genes in MSCs after 7 days. Fold increase in (A) COL1A1, (B) IBSP, (C) SP7,
(D) FGF2, (E) TGFB1, and (F) VEGFA. Data were normalized to RPL13 transcript level and then normalized to GM. Chart values represent mean6 SD for
n = 4; {p,0.001 vs. GM; #p,0.01 vs. GM; *p,0.05 vs. GM; $p,0.05 vs. OM.
doi:10.1371/journal.pone.0035579.g002
Figure 3. VEGF secretion by MSCs after 7 days of differenti-
ation. Chart values represent mean 6 SD for n = 4; {p,0.001 vs. GM;
*p,0.05 vs. OM.
doi:10.1371/journal.pone.0035579.g003
Proangiogenic Potential of MSCs
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Bischoff et al. demonstrated that dexamethone-containing
osteogenic media (OM+) stimulated secretion of the CXC family
of angiogenic chemokines, which are classified by a Glu-Leu-Arg
(ELR) motif located at the N-terminus [35]. The greatest
endothelial cell tubule branching was observed with OM+
conditioned media, which is in disagreement with the results of
this study. The discrepancy may be due to differences in plating
density, culture duration, and dilution of conditioned media.
Schubert et al. reported enhanced VEGF secretion from porcine
bone marrow-derived MSCs (BM-MSCs) following osteogenic
differentiation for 26 days compared to undifferentiated porcine
BM-MSCs [36]. While the effect of long-term differentiation on
the secretion of trophic factors is an important consideration, it is
necessary to minimize the duration of ex vivo culture and expansion
to capitalize on the acute application of cell-based therapies for
tissue engineering, thus motivating our examination of trophic
factor secretion over a shorter 7 day period.
Co-cultures of MSCs and endothelial cells enhance angiogenesis
in bone repair where establishment of an adequate vasculature
remains a significant challenge [37,38]. In these studies,
angiogenesis was also assessed using differentiated MSCs and
ECFCs in co-culture. Similar to our findings for tubule formation,
GM-conditioned MSCs were responsible for improving angiogen-
ic parameters, even in the absence of exogenous mitogenic growth
factors. Cell-cell contact was likely established in this sprouting
study because MSCs were seeded at high density within the gel
and are detected in close proximity to endothelial cells.
Importantly, these results validate the findings that co-cultures of
MSCs and endothelial cells can induce angiogenesis without the
addition of exogenous growth factors [37].
Our results provide detailed insight into the angiogenic trophic
factor secretion of MSCs as a function of early differentiation
toward osteoblasts. Moreover, these studies decouple the proan-
giogenic potential of MSCs from stimulation with osteogenic
supplements. Future work entails examining the proangiogenic
potential of MSCs differentiated for longer durations when co-
cultured with endothelial cells. Additionally, the precise role of
cell-cell signaling implicated in the angiogenic process must be
investigated.
Materials and Methods
Cell culture
Human bone marrow-derived MSCs (Lonza) were expanded
without further characterization in alpha-modified minimum
essential media (a-MEM, Invitrogen) supplemented with 10%
fetal bovine serum (FBS, JR Scientific) and 1% penicillin and
streptomycin (P/S, Mediatech). Cells were cultured under
standard conditions (37uC, 5% CO2, 21% O2) until use at passage
6. MSCs were seeded at 30,000 cells/cm2 in 12-well plates and
allowed to attach overnight. Thereafter, cells were cultured for 7
days in growth media (GM: a-MEM, 10% FBS, 1% P/S),
osteogenic media (OM: GM supplemented with 10 mM b-
glycerophosphate (bGP) and 50 mg/mL ascorbate-2-phosphate
(A2P)), or osteogenic media supplemented with 100 nM dexa-
methasone (OM+) [39], all from Sigma. For each experiment,
GM, OM, and OM+ aliquots were derived from the same batch of
Figure 4. Quantification of angiogenic cytokines in condi-
tioned media. (A) Conditioned GM and (B) original unconditioned GM
demonstrate serum contains trace amounts of angiogenic cytokines
save the positive (PC) and internal controls (IC). (C) Stacked column
chart of fluorescence (61000) of predominant angiogenic cytokines and
(D) VEGF fluorescence as a function of conditioned media. Data is
presented as median subtracted background fluorescence intensity and
normalized to positive controls and excluding inherent serum levels for
pooled conditioned media for n= 4.
doi:10.1371/journal.pone.0035579.g004
Figure 5. Endothelial cell proliferation measured through DNA
content in response to MSC-conditioned media. Data are
presented as fold decrease from conditioned GM. Neutralizing
VEGF165/121 antibody added at 10 mg/mL to conditioned media. Chart
values represent mean 6 SD for n = 3–4; {p,0.001 vs. conditioned GM;
#p,0.01 vs. conditioned OM.
doi:10.1371/journal.pone.0035579.g005
Proangiogenic Potential of MSCs
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serum containing a-MEM to ensure serum consistency. Media
changes were performed every 3 days.
Human umbilical cord blood endothelial colony forming cells
(ECFCs) were isolated using a protocol approved by the
Institutional Review Board of the Indiana University School of
Medicine as previously described [40]. Adherent ECFCs were
cultured under standard conditions in T-75 culture flasks coated
with 5 mg/cm2 rat tail collagen I (BD Biosciences) in SingleQuot-
supplemented endothelial cell growth media 2 (EGM2) (Lonza)
containing 10% FBS and 1% P/S. Growth factor-deficient media
(GF-Def EGM2) was prepared with serum-containing EGM2 but
lacking VEGF, FGF, and IGF, as these growth factors had the
most profound effect on mitogenicity (data not shown). Media
composition and nomenclature is detailed in Table 1.
Osteogenic potential
Intracellular alkaline phosphatase (ALP) expression was quali-
tatively observed after 7 days using a cytochemical stain and
quantitatively assessed using a colorimetric assay as previously
described [41]. For quantification, cells were rinsed in PBS,
collected in 500 mL passive lysis buffer (Promega), and sonicated at
40% amplitude for 5 s. Changes in ALP activity were determined
from the lysate using a routine p-nitrophenyl phosphate (PNPP)
colorimetric assay wherein absorbance is measured at 405 nm.
ALP activity was normalized to total DNA content from the same
cell lysate as quantified using Quant-iT PicoGreen dsDNA Assay
Kit (Invitrogen) according to the manufacturer’s protocol. Gene
expression as a function of osteogenic differentiation was assessed
by quantitative PCR as described below.
Quantitative PCR
Total RNA was collected using the RNeasy Mini kit (Qiagen) and
480 ng of total RNA was reverse-transcribed with the QuantiTect
Reverse Transcription Kit (Qiagen). qPCR was performed using
TaqMan1 Universal PCR Master Mix (Applied Biosystems) on a
Mastercycler1 realplex2 (Eppendorf). Primers and probes consisted of
COL1A1 (Hs01076777_m1), FGF2 (Hs00266645_m1), IBSP
(Hs00173720_m1) PDGFB (Hs00234042_m1), SP7 (Hs01866874_s1),
TGFB1 (Hs00998133_m1), and VEGFA (Hs00900055_m1) (Applied
Biosystems). Amplification conditions were 50uC for 2 min, 95uC for
10 min, followed by 40 cycles at 95uC for 15 s and 60uC for
1 min. Quantitative PCR results were normalized to RPL13
(Hs00204173_m1) transcript level to yield DCt. Fold changes between
GM were calculated to yield DDCt. Data is presented as 22DDCt and
Figure 6. Endothelial cell chemotaxis due to MSC-conditioned media. (A) GM, (B) GM with neutralizing 10 mg/mL VEGF165/121 antibody, (C)
OM, or (D) OM+. Images are representative of 4 wells. Scale bars represent 200 mm. (E) Fold increase in chemotaxis normalized to no gradient. Chart
values represent mean 6 SD for n= 4; {p,0.001 vs. GM.
doi:10.1371/journal.pone.0035579.g006
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standard deviation is calculated according to the manufacturer’s
protocol.
Proangiogenic protein secretion
The concentration of VEGF in conditioned media of MSCs
undergoing differentiation was determined using a human VEGF
ELISA kit according to the manufacturer’s protocol (R&D
Systems). After 7 days of differentiation, fresh media was added
and conditioned for 48 hrs prior to collection. Protein secretion
was normalized to DNA content of cells within the well.
Quantification of angiogenic proteins within conditioned media
was performed using a Human Angiogenesis Antibody Array
(RayBio). Pooled conditioned media from 4 replicates was applied
to one array well. Protein quantification was performed with a
GenePix 4000B scanner and associated GenePix Pro software
(Molecular Devices) to calculate median minus background
fluorescent intensity at 532 nm for each cytokine. Data is
normalized to positive controls and excludes protein concentra-
tions found in serum contained in unconditioned GM.
ECFC proliferation in conditioned media
The proliferative response of ECFCs to proangiogenic stimuli
was determined similar to previous studies [42]. Briefly, ECFCs
were seeded at 7,500 cells/cm2 in EGM2 in 12-well collagen-
coated culture plates and allowed to attach overnight. The next
day, culture media was refreshed with a 1:4 volume ratio of MSC-
conditioned media to GF-Def EGM2 and cultured for 72 hrs.
Each well was then rinsed with PBS to remove non-adherent cells
and debris. Proliferation was analyzed using Quant-iT PicoGreen
dsDNA Assay Kit (Invitrogen). Cells cultured in complete EGM2
served as the positive control, while cells cultured in EBM2 served
as the negative control. Cells cultured in 1:4 volume ratio of
unconditioned GM, OM, or OM+ to GF-Def EGM2 also served
as a control. For proliferation, migration, and tubule formation
experiments, exogenous VEGF in the conditioned media was
neutralized by the saturating addition of 10 mg/mL anti-human
VEGF16512/antibody (AB-293-NA, R&D Systems) [31] diluted in
PBS. Control groups were administered an equivalent volume of
PBS.
Figure 7. Endothelial cell tubulogenesis on Matrigel in the presence of MSC-conditioned media. (A) GM, (B) GM with neutralizing 10 mg/
mL VEGF165/121 antibody, (C) OM, or (D) OM+. Images are representative of 4 wells. Scale bars represent 500 mm. (E) Average number of branch points
and (F) Average tubule length in field of view. Chart values represent mean 6 SD for n = 4; {p,0.001 vs. GM; #p,0.01 vs. OM.
doi:10.1371/journal.pone.0035579.g007
Proangiogenic Potential of MSCs
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ECFC migration and tubule formation in conditioned
media
The potential of MSC-conditioned media to stimulate ECFC
migration [42] and tubule formation [43] was determined as
previously described. For migration, 24-well FluoroBlockTM
transwell inserts (3 mm pore size, BD Biosciences) were coated
with a thin layer of gelatin solution (0.1% fish oil gelatin, Sigma).
ECFCs (16105 cells/well) were seeded on the top of the transwell
inserts in 300 mL 1:4 unconditioned GM, OM, or OM+ to GF-
Def EGM2. Transwell inserts were then placed over 1 mL 1:4
conditioned GM, OM, or OM+ to GF-Def EGM2 to create a
positive chemotactic gradient. The no-gradient control consisted
of 1 mL GF-Def EGM2. Plates were then incubated for 24 hrs.
Cells that migrated through the transwell insert were stained via
calcein AM (3 mg/mL in PBS) for 30 min, and fluorescence was
quantitated using a microplate reader (Synergy HTTR) at 485/
530 nm and qualitatively captured using fluorescence microscopy.
For tubule formation, 100 mL of Growth Factor Reduced Matrigel
(BD Biosciences) was pipetted into 48-well plates and allowed to
gel at 37uC for 1 hr. ECFCs transduced to express green
fluorescent protein using a lentiviral vector (GFP-ECFCs) were
seeded on Matrigel at 30,000 cells/cm2 in GF-Def EGM2, and a
mixture of conditioned media and GF-Def EGM2 was added in a
1:4 volume ratio. Cells were cultured for 16 hrs, and images of
tubule formation were captured by fluorescence microscopy. We
calculated average tubule length, average branch number, and
average number of disrupted tubules from 25 tubules per field of
view using NIH ImageJ in 4 independent experiments. Prior to
analysis, images were randomized and descriptive markers were
removed to ensure unbiased evaluation.
Figure 8. Endothelial cell sprouting from microcarrier beads in co-culture with conditioned MSCs. (A) MSCs co-cultured with GFP-ECFCs
seeded on microcarrier beads are uniformly distributed within fibrin gels after 1 day. Representative sprouting observed when cultured with MSCs
conditioned in (B) GM, (C) OM, and (D) OM+ after 2 days. Images are representative of 4 wells. Scale bar in A represents 500 mm; scale bars in B–D
represent 100 mm. (E) Average number of sprouts per bead; (F) Average sprout length. Chart values represent mean 6 SD for n = 4; {p,0.001 vs. OM
and/or OM+; #p,0.01 vs. OM, *p,0.05 vs. OM+.
doi:10.1371/journal.pone.0035579.g008
Proangiogenic Potential of MSCs
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ECFC sprouting in fibrin co-cultures with conditioned
MSCs
The proangiogenic potential of osteogenically-induced MSCs
when co-cultured with ECFCs was further examined using a
sprouting assay as previously described [44]. Briefly, CytodexH
microcarrier beads (133–215 mm, Sigma) were swollen in PBS,
sterilized in 70% ethanol overnight, and washed repeatedly with
EGM2. In a flow cytometry sample tube, 2.5 mL of GF-Def
EGM2, 5,000 beads, and 46106 GFP-ECFCs were combined and
agitated every 20 min in an incubator. After 4 hrs, the contents
were transferred to a T-25 flask containing 2.5 mL of fresh GF-
Def EGM2 and incubated overnight in standard cell culture
position. Conditioned MSCs were fluorescently tagged with
CellTrackerTM Orange (Invitrogen) according to the manufactur-
er’s protocol. In GF-Def EGM2, 2 mg/mL fibrinogen (Calbio-
chem) was prepared. The fibrinogen solution (400 mL) was mixed
with 50 mL of 50,000 MSCs resuspended in GM and 100 mL of
the GFP-ECFC-bead suspension and subsequently polymerized
with 0.625 U/mL thrombin (Sigma) in a single well of a 24-well
plate. Gels were incubated for 25 min in standard culture
conditions prior to addition of 1 mL GF-Def EGM2. Media was
changed the following day and every other day thereafter. Images
were captured using fluorescence microscopy for 3 days. Sprouting
was quantified using previously described methods [45]. Briefly, 5
beads per gel in each of 4 gels were analyzed for each condition.
Vessel segments for each bead were traced, counted, and
quantified using ImageJ. The resulting values of average number
of sprouts and average sprout length for 20 beads per condition
were tabulated and averaged.
Statistical analysis
Data are presented as mean 6 standard deviation from at least
three independent experiments. Statistical significance was
assessed by one-way ANOVA followed by a Student-Newman–
Keuls post hoc test, and p-values,0.05 were considered
statistically significant. Statistical analysis was performed using
GraphPad PrismH4 analysis software (GraphPad Software).
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